New pill combo aims to keep blood cancer at bay

NCT ID NCT07154264

Recruiting now Disease control Sponsor: Dizal Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing a combination of two oral drugs, DZD8586 and venetoclax, in people with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have not yet been treated. The study will first check safety, then see if the combination can keep the cancer from progressing for at least two years. About 66 adults will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DZD8586 (birelentinib) and venetoclax
What this could lead to: If successful, this combination could offer a new treatment option that helps control CLL/SLL for longer without the disease getting worse.
What could go wrong: This is an early phase 2 study with only 66 people, so results may not apply to everyone. Side effects from the drug combination are possible and not yet fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia chronic lymphocytic leukemia/small lymphocytic lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Contacts and locations

Locations

Affiliated Hospital of Nantong University
RECRUITING

Nantong, Jiangsu, 226001, China
Anhui Provincial Cancer Hospital
RECRUITING

Hefei, Anhui, 230031, China
Henan Cancer Hospital
RECRUITING

Zhengzhou, Henan, 450008, China
Hunan Cancer Hospital
RECRUITING

Changsha, Hunan, 410013, China
Nanfang Hospital, Southern Medical University
RECRUITING

Guangzhou, Guangdong, 510515, China
Peking University Third Hospital
RECRUITING

Beijing, Beijing Municipality, 100191, China
Shengjing Hospital of China Medical University
NOT_YET_RECRUITING

Shenyang, Liaoning, 110004, China
The First Affiliated Hospital of Nanchang University
RECRUITING

Nanchang, Jiangxi, 330006, China
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310003, China
The First Bethune Hospital of Jilin University
RECRUITING

Changchun, Jilin, 130021, China
The First People's Hospital of Changzhou
RECRUITING

Changzhou, Jiangsu, 213003, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, 430022, China
West China Hospital of Sichuan University
RECRUITING

Chengdu, Sichuan, 610041, China
Yichang Central People's Hospital
RECRUITING

Yichang, Hubei, 443003, China
Zhujiang Hospital of Southern Medical University
RECRUITING

Guangzhou, Guangdong, 510280, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.